The Biotechnology Lab is wrapping its collaboration work with the NICHD and NIAID on the development of new conjugated vaccines against Shigella flexneri, Shigella Sonnie, Bortedella pertussis Haemophilus influenzae type A, Bortedella pertussis, and protein vaccines for Bacillus anthracis and Malaria transmission blocking vaccine. Working together with scientists from the FDA, the laboratory is evaluating the potential production of influenza virus vaccine form the newly developed MDCK cells, and on the structure of the polysaccharide from E. coli K1 and Meningococcal C. The Biotechnology Lab continued to work on the development of new production approaches for viral vaccines by using suspension cell culture, concentrating on influenza and rotavirus. In addition we are working on expressing the respiratory syncytial Virus (RSV) fusion protein from HEK cells growing in suspension in bioreactor. The proper constructs are being made and preliminary experiments on expression and purifications are being conducted.
|Robbins, John B; Schneerson, Rachel; Kubler-Kielb, Joanna et al. (2014) Toward a new vaccine for pertussis. Proc Natl Acad Sci U S A 111:3213-6|
|Battistel, Marcos D; Shangold, Michael; Trinh, Loc et al. (2012) Evidence for helical structure in a tetramer of Î±2-8 sialic acid: unveiling a structural antigen. J Am Chem Soc 134:10717-20|
|Bellanti, Joseph A; Lin, Feng-Ying C; Chu, Chiayung et al. (2012) Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis. Clin Vaccine Immunol 19:140-5|
|Cui, Xizhong; Su, Junwu; Li, Yan et al. (2010) Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensive Care Med 36:148-56|
|Chu, Chia; Lugovtsev, Vladimir; Lewis, Andrew et al. (2010) Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor. Vaccine :|
|Passwell, Justen H; Ashkenzi, Shai; Banet-Levi, Yonit et al. (2010) Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 28:2231-5|